LPL Financial LLC Boosts Stock Position in INmune Bio, Inc. (NASDAQ:INMB)

LPL Financial LLC grew its position in shares of INmune Bio, Inc. (NASDAQ:INMB) by 33.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 19,072 shares of the company’s stock after purchasing an additional 4,730 shares during the quarter. LPL Financial LLC owned approximately 0.09% of INmune Bio worth $89,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Raymond James Financial Inc. bought a new position in INmune Bio during the fourth quarter valued at approximately $2,221,000. State Street Corp grew its holdings in shares of INmune Bio by 35.1% during the 3rd quarter. State Street Corp now owns 226,428 shares of the company’s stock valued at $1,220,000 after purchasing an additional 58,838 shares during the last quarter. Barclays PLC grew its holdings in shares of INmune Bio by 601.9% during the 3rd quarter. Barclays PLC now owns 29,044 shares of the company’s stock valued at $157,000 after purchasing an additional 24,906 shares during the last quarter. Geode Capital Management LLC raised its position in INmune Bio by 6.6% in the 3rd quarter. Geode Capital Management LLC now owns 344,466 shares of the company’s stock worth $1,857,000 after purchasing an additional 21,262 shares during the period. Finally, Westside Investment Management Inc. lifted its stake in INmune Bio by 26.2% in the fourth quarter. Westside Investment Management Inc. now owns 89,975 shares of the company’s stock worth $420,000 after purchasing an additional 18,660 shares during the last quarter. 12.72% of the stock is owned by hedge funds and other institutional investors.

INmune Bio Price Performance

Shares of NASDAQ:INMB opened at $7.59 on Friday. The stock’s 50-day moving average is $7.76 and its 200 day moving average is $6.77. The company has a market cap of $174.45 million, a PE ratio of -3.48 and a beta of 1.86. INmune Bio, Inc. has a 1 year low of $4.32 and a 1 year high of $11.99.

INmune Bio (NASDAQ:INMB) last posted its earnings results on Thursday, March 27th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.14. Analysts expect that INmune Bio, Inc. will post -2.24 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently commented on INMB. Maxim Group lifted their price objective on INmune Bio from $22.00 to $30.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. Scotiabank lifted their price target on INmune Bio from $22.00 to $23.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, February 11th. RODMAN&RENSHAW upgraded INmune Bio to a “strong-buy” rating in a research report on Tuesday, January 28th. Finally, Rodman & Renshaw initiated coverage on shares of INmune Bio in a report on Tuesday, January 28th. They issued a “buy” rating and a $23.00 target price on the stock. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $22.80.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.